Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis

Kaundal U, Tsou PS, Sahu M, Huang M, Boyden SE, Woodford CM, Shriner D, Stenson E, Safran SA, Zhou Y, Talley TA, Gudapati K, Zhang[...]

Single-cell analysis reveals peripheral helper T cells in rheumatoid arthritis-related interstitial lung disease

Suga K, Seng A, Yao C, Parimon T, Singaraju A, Israely E, Samuel BER, Choi YJ, Fert-Bober J, Stripp BR, Wolters PJ, Giles JT, Chen[...]

Artificial Intelligence-derived Measurements of Myosteatosis from Coronary Artery Calcium CT Scans to Predict COPD: The Multi-Ethnic Study of Atherosclerosis

Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, de-Torres JP, Seijo LM, Mechanick[...]